Nectar Lifesciences Current Share Price | Nectar Lifesciences Stock Screener
NECLIFE
Pharmaceuticals
Nectar Lifesciences Current Stock Price Today
Live Share Price NSE
₹10.98
▼
-0.04 (-0.36%)
Live Share Price BSE
₹11.01
▼
-0.10 (-0.90%)
As of September 18, 2026, the live Nectar Lifesciences share price (NSE: NECLIFE) is ₹10.98 on NSE and ₹11.01 on BSE, down 0.36% from the previous close, with shares trading between ₹10.85 and ₹11.30 in today's trading session, and a 52-week range of ₹9.30–₹20.95.
Browse NECLIFE complete financial statements to support your investment research.
Use the Nectar Lifesciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Nectar Lifesciences Market Cap
₹223.40 Cr.
NECLIFE P/E Ratio (TTM)
-0.95
Nectar Lifesciences P/B Ratio
0.40
EPS (TTM)
₹-13.40
Dividend Yield
-
Debt to Equity
0.38
NECLIFE 52 Week High
₹20.95
Nectar Lifesciences 52 Week Low
₹9.30
Operating Margin
-
Profit Margin
-1133.33%
NECLIFE Revenue (TTM)
₹6.00
EBITDA
₹-83.00
Net Income
₹-68.00
Total Assets
₹622.00
Total Equity
₹582.00
Nectar Lifesciences Current Share Price Chart
Track the current Nectar Lifesciences share price and stock price with an interactive chart. Analyse NECLIFE price trends, trading volume, historical performance, and volatility across different timeframes — the complete Nectar Lifesciences stock quote in one place.
Nectar Lifesciences Company Profile - Fundamental Screener
Screen Nectar Lifesciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for NECLIFE shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE023H01027
Nectar Lifesciences Balance Sheet Screener
Screen NECLIFE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 622 | 2,047 | 2,191 | 2,189 | 2,391 | 2,471 | 2,633 | 2,705 | 2,724 | 2,581 |
| Current Assets | 253 | 1,238 | 1,284 | 1,231 | 1,355 | 1,239 | 1,615 | 1,669 | 1,661 | 1,496 |
| Fixed Assets | 105 | 633 | 643 | 662 | 723 | 772 | 785 | 825 | 852 | 881 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 13 | 70 | 149 | 234 | 299 | 222 | 249 | 300 | 356 | 296 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 582 | 956 | 1,069 | 1,065 | 1,088 | 1,062 | 1,136 | 1,105 | 1,059 | 1,007 |
| Share Capital | 19 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
| Reserves & Surplus | 563 | 934 | 1,047 | 1,042 | 1,066 | 1,040 | 1,114 | 1,083 | 1,036 | 984 |
Nectar Lifesciences Income Statement Screener - Profit & Revenue Analysis
Screen Nectar Lifesciences income statement and profit fundamentals.
Analyze NECLIFE quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Nectar Lifesciences share price evaluation.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6 | 3 | 0 | 6 | 0 | 36 | 441 | 359 | 12 | 8 | 406 | 395 | 409 | 453 | 477 |
| Expenses | 89 | 28 | 130 | 69 | 177 | 2 | 393 | 320 | 6 | 0 | 371 | 359 | 371 | 410 | 427 |
| EBITDA | -83 | -25 | -130 | -63 | -176 | 34 | 49 | 40 | 6 | 8 | 35 | 36 | 38 | 43 | 50 |
| Operating Profit % | 0.00% | -277000.00% | 0.00% | -1212.00% | 0.00% | 0.00% | 11.00% | 11.00% | -10.00% | 0.00% | 4.00% | 9.00% | 7.00% | 9.00% | 10.00% |
| Depreciation | 0 | 0 | 0 | 1 | 0 | 0 | 15 | 16 | 0 | 0 | 15 | 15 | 15 | 15 | 14 |
| Interest | 6 | 0 | 0 | 0 | 0 | 30 | 24 | 20 | 0 | 0 | 20 | 18 | 21 | 25 | 17 |
| Profit Before Tax | -88 | -24 | -130 | -64 | -176 | 3 | 11 | 5 | 6 | 8 | 2 | 3 | 2 | 3 | 18 |
| Tax | -20 | -9 | 0 | 0 | 0 | -11 | 11 | 2 | 0 | 0 | -2 | 1 | 1 | 1 | 6 |
| Net Profit | -68 | -15 | -130 | -63 | -176 | 14 | 1 | 3 | 6 | 8 | 4 | 2 | 1 | 2 | 12 |
| EPS | -3.38 | -0.79 | -5.80 | -2.82 | -7.85 | 0.64 | 0.03 | 0.13 | 0.25 | 0.35 | 0.16 | 0.08 | 0.05 | 0.07 | 0.52 |
Nectar Lifesciences Cash Flow Screener - Liquidity Fundamentals
Screen NECLIFE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -349 | 169 | 225 | 134 | 95 | 21 | 285 | 239 | 65 | 199 |
| Investing Activities | 1,208 | -42 | -17 | 52 | 17 | -29 | -33 | -26 | -29 | -18 |
| Financing Activities | -767 | -128 | -205 | -186 | -119 | 12 | -252 | -201 | -40 | -204 |
| Net Cash Flow | 93 | -1 | 2 | 0 | -8 | 4 | 0 | 12 | -4 | -24 |
Nectar Lifesciences Shareholding Pattern Screener
See Nectar Lifesciences shareholding pattern with promoter, FII, and DII holdings.
Check Nectar Lifesciences promoter holding and ownership changes for NECLIFE on TickJournal.
| Item | 2026-Jan | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 51.84% | 51.84% | 51.84% | 44.53% | 44.53% | 44.91% | 44.91% | 55.80% |
| FII Holding | 0.58% | 0.60% | 0.50% | 1.65% | 0.81% | 0.62% | 0.52% | 16.97% |
| DII Holding | 3.54% | 4.01% | 3.74% | 0.16% | 0.19% | 0.09% | 5.82% | 0.00% |
| Govt Holding | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% |
| Public Holding | 35.83% | 36.23% | 37.58% | 41.60% | 44.12% | 44.70% | 39.72% | 23.32% |
| Other Holding | 8.18% | 7.29% | 6.32% | 12.04% | 10.32% | 9.67% | 9.00% | 3.88% |
| Shareholder Count | 76,648 | 74,834 | 73,834 | 69,241 | 71,977 | 76,470 | 78,124 | 59,946 |
Nectar Lifesciences Share Dividend Screener - Share Yield Analysis
Check Nectar Lifesciences dividend history with payout and yield data.
View Nectar Lifesciences dividend details including ex-dates and amounts for NECLIFE stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.05 | 0.27% |
| 2019-March | ₹0.05 | 0.51% |
| 2018-March | ₹0.05 | 0.29% |
| 2017-March | ₹0.05 | 0.19% |
Nectar Lifesciences Stock Index Membership
See which indices include Nectar Lifesciences stock.
Check NECLIFE index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Nectar Lifesciences Market Events Screener - Corporate Actions
Get Nectar Lifesciences corporate actions including splits, bonuses, and buybacks.
Check Nectar Lifesciences stock events that may affect NECLIFE share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-18 | 2026-09-18 | Annual General Meeting | NA | 9.32% |
| 2026-08-14 | 2026-08-14 | Quarterly Result Announcement | NA | 7.18% |
| 2026-05-30 | 2026-05-30 | Quarterly Result Announcement | NA | 2.64% |
| 2026-01-23 | 2026-01-23 | Quarterly Result Announcement | NA | -4.39% |
| 2025-12-24 | 2026-12-31 | Buyback | 27 | -2.67% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 8.67% |
| 2025-09-29 | 2025-09-29 | Annual General Meeting | NA | -5.38% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | 8.63% |
| 2025-08-04 | 2025-08-04 | Extraordinary General Meeting | NA | -28.38% |
| 2025-07-07 | 2025-07-07 | Quarterly Result Announcement | NA | -9.42% |
| 2025-01-31 | 2025-01-31 | Quarterly Result Announcement | NA | -18.01% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -11.31% |
| 2024-09-21 | 2024-09-21 | Annual General Meeting | NA | 41.10% |
Nectar Lifesciences Competitors Screener - Peer Comparison
Screen NECLIFE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 441,478 | 36.91 | 61,674 | 12.69% | 11,565 | 34.00 |
| Divis Laboratories | 247,470 | 85.36 | 11,067 | 13.95% | 2,568 | 63.65 |
| Torrent Pharmaceuticals | 188,872 | 86.95 | 13,886 | 20.34% | 2,138 | 52.16 |
| Zydus Life Science | 112,608 | 24.28 | 27,658 | 17.64% | 5,026 | 45.64 |
| Cipla | 110,352 | 33.22 | 29,045 | 2.24% | 3,870 | 35.27 |
| Laurus Labs | 106,298 | 95.94 | 6,868 | 22.01% | 890 | 68.28 |
| Dr Reddys Laboratories | 97,281 | 29.91 | 35,059 | 3.90% | 4,158 | 47.72 |
| Aurobindo Pharma | 96,652 | 25.88 | 34,145 | 5.56% | 3,503 | 57.04 |
| Lupin | 95,790 | 17.09 | 29,039 | 26.75% | 5,356 | 28.17 |
| Mankind Pharma | 94,163 | 44.87 | 14,636 | 14.85% | 1,938 | 37.57 |
Nectar Lifesciences Company Announcements - News Screener
Screen NECLIFE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-08-22 | Letter Sent To Members | - |
| 2026-08-21 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-20 | Reg. 34 (1) Annual Report. | - |
| 2026-08-20 | Notice Of 31St Annual General Meeting (AGM) For The Financial Year 2025-26 | - |
| 2026-08-20 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-15 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-15 | Announcement under Regulation 30 (LODR)-Change in Corporate Office Address | - |
| 2026-08-14 | Book Closure/ Cut-Off Date For The Purpose Of 31St Annual General Meeting (AGM) For The Financial Year (FY) 2025-26 | - |
| 2026-08-14 | Board Meeting Outcome for 31St Annual General Meeting ("AGM") To Be Held On 18-09-2026 And Other Business Matters. | - |
| 2026-08-14 | Unaudited Standalone And Consolidated Financial Results For The Quarter Ended On June 30 2026 | - |
| 2026-08-10 | Board Meeting Intimation for Financial Results And Other Business Matters. | - |
| 2026-08-06 | Announcement under Regulation 30 (LODR)-Resignation of Director | - |
| 2026-08-04 | Sale And Surrender Of Leasehold Rights In Land Situated In Jammu | - |
| 2026-07-23 | Update On Slump Sale | - |
| 2026-07-11 | Announcement under Regulation 30 (LODR)-Change in Registered Office Address | - |
| 2026-07-04 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-24 | Closure of Trading Window | - |
| 2026-06-16 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-06-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-30 | Financial Results For The Year 2025-26 | - |